Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Inflazyme Pharmaceuticals (T.IZP) -- Ignore unavailable to you. Want to Upgrade?

To: Chuca Marsh who wrote (1332)	11/16/1999 11:29:00 PM
From: Sean Janzen	Respond to of 1501

Charles, Thanks for the post. I remember when you introduced ICOS, icos.com , to this board almost 4 years ago. They are also conducting research on PDE inhibitors. This is what they have to say: RESEARCH "...IC351 is an example of how knowledge of over 50 distinct phosphodiesterase enzymes was leveraged to produce a drug with a very favorable selectivity profile. This theme continues with the PDE type 4 inhibitors, discovered by ICOS scientists, that are potent, highly selective and, importantly, may lack the side effects of vomiting and sedation. These untoward effects have, in the past, limited the utility of drugs against PDE4. Our PDE4 product candidates, currently in preclinical tests, have demonstrated inhibition of production of tumor necrosis factor. This mechanism of action has been proven effective for rheumatoid arthritis - which is one potential application for these molecules... " From the following paragraphs it looks like their program is at the same level as IZP's. Best of luck to IZP in 2000. PDE Selective Inhibitors status: preclinical primary indication: inflammatory diseases ICOS scientists recognize the importance of phosphodiesterases, (PDEs), a family of enzymes that degrade intracellular second messengers, called cyclic nucleotides. Basic research demonstrated that inhibitors of the type 4 PDE (PDE4) increase cAMP, a cyclic nucleotide, and attenuate cellular responses in many proinflammatory cell types. ICOS has a number of potent PDE4-selective inhibitors currently being evaluated in various disease models of inflammation.